CULLINAN THERAPEUTICS INC (CGEM)
US2300311063 - Common Stock
Interesting CGEM Put And Call Options For September 20th
Notable Tuesday Option Activity: CGEM, OKTA, Z
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion...
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing...
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cullinan Oncology (NASDAQ:CGEM) just reported results for the first quarter of ...
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978...
Interesting CGEM Put And Call Options For April 2025
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...
Interesting CGEM Put And Call Options For June 21st
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical...
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to...
Commit To Purchase Cullinan Oncology At $7.50, Earn 6.2% Annualized Using Options
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cullinan Oncology (NASDAQ:CGEM) just reported results for the fourth quarter of...